Shanghai Xiyuan Biotechnology

Shanghai Xiyuan Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic virus therapies. Founded by Dr. Hu Fang, the pioneer behind the world's first approved oncolytic virus (Oncorine), the company focuses on engineering next-generation viral vectors to treat refractory solid tumors. Their lead candidate, XY01, is an optimized oncolytic adenovirus currently undergoing Phase 2 clinical trials in China for head and neck cancers. Xiyuan's technology platform emphasizes enhancing viral replication selectivity and stimulating systemic anti-tumor immunity. The company is headquartered in Shanghai and aims to bridge the gap between traditional gene therapy and modern immunotherapy.